---
title: "Liberty Global -C | 8-K: FY2026 Q2 Revenue: USD 1.172 B"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293756095.md"
datetime: "2026-07-24T12:21:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293756095.md)
  - [en](https://longbridge.com/en/news/293756095.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293756095.md)
generator: "portal-rs"
---

# Liberty Global -C | 8-K: FY2026 Q2 Revenue: USD 1.172 B

Revenue: As of FY2026 Q2, the actual value is USD 1.172 B.

No specific financial or operational metrics, nor any outlook or guidance content, can be extracted from the provided reference. The reference, a Form 8-K filing by Liberty Global Ltd., indicates that a press release announcing operating and financial results for the quarter ended June 30, 2026, was issued, but the actual content of this press release, which would contain the requested data, is not included within the provided text for analysis.

### Related Stocks

- [LBTYK.US](https://longbridge.com/en/quote/LBTYK.US.md)

## Related News & Research

- [Olenox converts $4.5 million Series C preferred stock into common shares](https://longbridge.com/en/news/297915030.md)
- [Citigroup Stock: Is C Outperforming the Financial Sector?](https://longbridge.com/en/news/297808110.md)
- [Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | PBYI Stock News](https://longbridge.com/en/news/297960805.md)
- [ZoomInfo Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | GTM Stock News](https://longbridge.com/en/news/297958221.md)
- [Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | KURA Stock News](https://longbridge.com/en/news/298032682.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**